+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Tumor-Infiltrating Lymphocyte Therapy Market - Global Forecast 2026-2032- Product Image
Tumor-Infiltrating Lymphocyte Therapy Market - Global Forecast 2026-2032- Product Image
New

Tumor-Infiltrating Lymphocyte Therapy Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 195 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 6081124
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Tumor-Infiltrating Lymphocyte Therapy Market is at a pivotal stage, with industry momentum shaped by clinical validation, operational advancements, and supply chain adaptation. As cell-based immuno-oncology evolves, TIL therapy stands out for its capacity to translate tumor-resident immune recognition into clinically meaningful and scalable outcomes.

Market Snapshot: Tumor-Infiltrating Lymphocyte Therapy Market Overview

The global Tumor-Infiltrating Lymphocyte Therapy Market expanded from USD 480.79 million in 2025 to USD 552.92 million in 2026. Projected to grow at a CAGR of 18.74%, it is anticipated to achieve a market value of USD 1.60 billion by 2032.

Scope & Segmentation

This report delivers a granular analysis of the TIL therapy ecosystem, spanning therapy variants, cancer types, end users, distribution pathways, and regional readiness. The segments covered include:

  • Therapy Types: Focus on autologous TIL approaches, with comparisons against other autologous cell modalities for operational and clinical context.
  • Cancer Indications: Melanoma, cervical, head and neck, lung, and other solid tumors where tumor tissue accessibility and immune competence drive clinical interest.
  • End Users: High-volume academic cancer centers, hospitals, specialty centers, and dedicated cell therapy facilities, each with different capacities for TIL therapy delivery.
  • Distribution Channels: Direct-to-hospital and specialty distribution models, highlighting impacts on scheduling, chain-of-identity, and system-wide integration.
  • Regions: Americas, EMEA, and Asia-Pacific, analyzed for infrastructure strength, regulatory familiarity, and healthcare logistics.
  • Enabling Technologies: Automation, closed-system manufacturing, digital chain-of-identity solutions, and platforms that streamline tissue processing and T-cell expansion.

Key Takeaways for Senior Decision-Makers

  • TIL therapy occupies a unique position in cell-based oncology by converting a patient’s natural immune response into scalable therapy, particularly where existing approaches have limited durability.
  • A shift from bespoke academic protocols toward industrialized and standardized platforms is reducing variability and bridging the gap between research potential and operational reality.
  • Manufacturing innovations—process control, automation, and robust chain-of-custody—have become strategic imperatives to enable reliable turnaround and sustainable scalability.
  • Regional differences are pronounced: the Americas benefit from established infrastructure and trial networks; EMEA’s adoption pace is influenced by reimbursement strategies; Asia-Pacific growth centers on local partnerships and regulatory alignment.
  • Site enablement, including efficient training, streamlined scheduling, and coordinated care, is now a critical factor for successful expansion beyond early adopters.

Tariff Impact on TIL Therapy Supply Chains

Anticipated US tariffs in 2025 introduce new cost and complexity considerations for the TIL therapy ecosystem. The sector's reliance on imported single-use consumables, bioprocess equipment, and specialized packaging could increase supply volatility and procurement risk, particularly for margin-sensitive manufacturing. Tariffs on capital-intensive technologies may delay capacity expansion, prolong legacy equipment cycles, and exert pressure on operational timelines. To counter these challenges, market leaders are adopting dual-sourcing, buffer inventories, adjusted contracting, and exploring domestic production pathways. Tariff preparedness is crucial for protecting the full vein-to-vein process and maintaining care delivery reliability.

Methodology & Data Sources

This analysis integrates systematic landscape mapping, public and proprietary documentation review, and structured interviews with clinical, regulatory, manufacturing, and commercial stakeholders. Findings are validated through cross-stakeholder triangulation to ensure accuracy and practical relevance for B2B executives.

Why This Report Matters

  • Clarifies operational and strategic implications of TIL therapy adoption across diverse healthcare and commercial environments.
  • Enables better decision-making on site selection, capacity planning, and supply chain risk mitigation.
  • Equips senior leaders with actionable benchmarks and frameworks aligned to emerging technology, regulatory, and real-world practice trends.

Conclusion

TIL therapy’s future will be shaped by operational excellence, resilient supply networks, and integration within real-world oncology pathways. Strategic execution and adaptive infrastructure are essential for realizing its full potential as a targeted immuno-oncology solution.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Tumor-Infiltrating Lymphocyte Therapy Market, by Indication
8.1. Breast Cancer
8.2. Lung Cancer
8.3. Melanoma
9. Tumor-Infiltrating Lymphocyte Therapy Market, by Cell Source
9.1. Allogeneic
9.2. Autologous
10. Tumor-Infiltrating Lymphocyte Therapy Market, by Manufacturing Model
10.1. Contract Manufacturing Organization
10.2. In-House Manufacturing
11. Tumor-Infiltrating Lymphocyte Therapy Market, by End User
11.1. Hospitals
11.2. Research Institutes
11.3. Specialty Clinics
12. Tumor-Infiltrating Lymphocyte Therapy Market, by Distribution Channel
12.1. Hospital Pharmacy
12.2. Online Pharmacy
12.3. Retail Pharmacy
13. Tumor-Infiltrating Lymphocyte Therapy Market, by Region
13.1. Americas
13.1.1. North America
13.1.2. Latin America
13.2. Europe, Middle East & Africa
13.2.1. Europe
13.2.2. Middle East
13.2.3. Africa
13.3. Asia-Pacific
14. Tumor-Infiltrating Lymphocyte Therapy Market, by Group
14.1. ASEAN
14.2. GCC
14.3. European Union
14.4. BRICS
14.5. G7
14.6. NATO
15. Tumor-Infiltrating Lymphocyte Therapy Market, by Country
15.1. United States
15.2. Canada
15.3. Mexico
15.4. Brazil
15.5. United Kingdom
15.6. Germany
15.7. France
15.8. Russia
15.9. Italy
15.10. Spain
15.11. China
15.12. India
15.13. Japan
15.14. Australia
15.15. South Korea
16. United States Tumor-Infiltrating Lymphocyte Therapy Market
17. China Tumor-Infiltrating Lymphocyte Therapy Market
18. Competitive Landscape
18.1. Market Concentration Analysis, 2025
18.1.1. Concentration Ratio (CR)
18.1.2. Herfindahl Hirschman Index (HHI)
18.2. Recent Developments & Impact Analysis, 2025
18.3. Product Portfolio Analysis, 2025
18.4. Benchmarking Analysis, 2025
18.5. Achilles Therapeutics
18.6. Adaptimmune Therapeutics plc
18.7. Anocca AB
18.8. Atreca Inc.
18.9. Cellectis S.A.
18.10. Celularity Inc.
18.11. GammaDelta Therapeutics Ltd.
18.12. Immatics N.V.
18.13. Instil Bio Inc.
18.14. Iovance Biotherapeutics Inc.
18.15. Kite Pharma Inc
18.16. Lyell Immunopharma Inc.
18.17. Nykode Therapeutics ASA
18.18. Obsidian Therapeutics Inc.
18.19. PACT Pharma Inc.
18.20. Poseida Therapeutics Inc.
18.21. Precigen Inc.
18.22. RheinCell Therapeutics GmbH
18.23. SQZ Biotechnologies Company
18.24. Tessa Therapeutics Ltd.
18.25. TILT Biotherapeutics
18.26. TScan Therapeutics Inc.
18.27. Turnstone Biologics Corp.
List of Figures
FIGURE 1. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CELL SOURCE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. UNITED STATES TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 13. CHINA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY LUNG CANCER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MELANOMA, BY REGION, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MELANOMA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MELANOMA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY ALLOGENEIC, BY REGION, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY ALLOGENEIC, BY GROUP, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY ALLOGENEIC, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY AUTOLOGOUS, BY REGION, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY AUTOLOGOUS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY AUTOLOGOUS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CONTRACT MANUFACTURING ORGANIZATION, BY REGION, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CONTRACT MANUFACTURING ORGANIZATION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CONTRACT MANUFACTURING ORGANIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY IN-HOUSE MANUFACTURING, BY REGION, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY IN-HOUSE MANUFACTURING, BY GROUP, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY IN-HOUSE MANUFACTURING, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 47. AMERICAS TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 48. AMERICAS TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 49. AMERICAS TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
TABLE 50. AMERICAS TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2018-2032 (USD MILLION)
TABLE 51. AMERICAS TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 52. AMERICAS TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 53. NORTH AMERICA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 54. NORTH AMERICA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 55. NORTH AMERICA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
TABLE 56. NORTH AMERICA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2018-2032 (USD MILLION)
TABLE 57. NORTH AMERICA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 58. NORTH AMERICA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 59. LATIN AMERICA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 60. LATIN AMERICA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 61. LATIN AMERICA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
TABLE 62. LATIN AMERICA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2018-2032 (USD MILLION)
TABLE 63. LATIN AMERICA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 64. LATIN AMERICA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 65. EUROPE, MIDDLE EAST & AFRICA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 66. EUROPE, MIDDLE EAST & AFRICA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 67. EUROPE, MIDDLE EAST & AFRICA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
TABLE 68. EUROPE, MIDDLE EAST & AFRICA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2018-2032 (USD MILLION)
TABLE 69. EUROPE, MIDDLE EAST & AFRICA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 70. EUROPE, MIDDLE EAST & AFRICA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 71. EUROPE TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 72. EUROPE TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 73. EUROPE TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
TABLE 74. EUROPE TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2018-2032 (USD MILLION)
TABLE 75. EUROPE TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 76. EUROPE TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 77. MIDDLE EAST TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 78. MIDDLE EAST TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 79. MIDDLE EAST TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
TABLE 80. MIDDLE EAST TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2018-2032 (USD MILLION)
TABLE 81. MIDDLE EAST TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 82. MIDDLE EAST TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 83. AFRICA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 84. AFRICA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 85. AFRICA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
TABLE 86. AFRICA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2018-2032 (USD MILLION)
TABLE 87. AFRICA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 88. AFRICA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 89. ASIA-PACIFIC TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 90. ASIA-PACIFIC TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 91. ASIA-PACIFIC TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
TABLE 92. ASIA-PACIFIC TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2018-2032 (USD MILLION)
TABLE 93. ASIA-PACIFIC TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 94. ASIA-PACIFIC TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 95. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 96. ASEAN TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 97. ASEAN TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 98. ASEAN TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
TABLE 99. ASEAN TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2018-2032 (USD MILLION)
TABLE 100. ASEAN TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 101. ASEAN TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 102. GCC TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 103. GCC TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 104. GCC TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
TABLE 105. GCC TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2018-2032 (USD MILLION)
TABLE 106. GCC TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 107. GCC TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 108. EUROPEAN UNION TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 109. EUROPEAN UNION TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 110. EUROPEAN UNION TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
TABLE 111. EUROPEAN UNION TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2018-2032 (USD MILLION)
TABLE 112. EUROPEAN UNION TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 113. EUROPEAN UNION TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 114. BRICS TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 115. BRICS TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 116. BRICS TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
TABLE 117. BRICS TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2018-2032 (USD MILLION)
TABLE 118. BRICS TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 119. BRICS TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 120. G7 TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 121. G7 TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 122. G7 TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
TABLE 123. G7 TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2018-2032 (USD MILLION)
TABLE 124. G7 TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 125. G7 TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 126. NATO TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 127. NATO TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 128. NATO TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
TABLE 129. NATO TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2018-2032 (USD MILLION)
TABLE 130. NATO TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 131. NATO TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 132. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 133. UNITED STATES TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 134. UNITED STATES TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 135. UNITED STATES TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
TABLE 136. UNITED STATES TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2018-2032 (USD MILLION)
TABLE 137. UNITED STATES TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 138. UNITED STATES TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 139. CHINA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 140. CHINA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 141. CHINA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
TABLE 142. CHINA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2018-2032 (USD MILLION)
TABLE 143. CHINA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 144. CHINA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

Companies Mentioned

The key companies profiled in this Tumor-Infiltrating Lymphocyte Therapy market report include:
  • Achilles Therapeutics
  • Adaptimmune Therapeutics plc
  • Anocca AB
  • Atreca Inc.
  • Cellectis S.A.
  • Celularity Inc.
  • GammaDelta Therapeutics Ltd.
  • Immatics N.V.
  • Instil Bio Inc.
  • Iovance Biotherapeutics Inc.
  • Kite Pharma Inc
  • Lyell Immunopharma Inc.
  • Nykode Therapeutics ASA
  • Obsidian Therapeutics Inc.
  • PACT Pharma Inc.
  • Poseida Therapeutics Inc.
  • Precigen Inc.
  • RheinCell Therapeutics GmbH
  • SQZ Biotechnologies Company
  • Tessa Therapeutics Ltd.
  • TILT Biotherapeutics
  • TScan Therapeutics Inc.
  • Turnstone Biologics Corp.

Table Information

Report AttributeDetails
No. of Pages195
PublishedJanuary 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 552.92 Million
Forecasted Market Value ( USD ) by 2032 $ 1600 Million
Compound Annual Growth Rate18.7%
Regions CoveredGlobal
No. of Companies Mentioned24

Related Topics

Related Reports

Global Tumor Infiltrating Lymphocytes Therapy Market Opportunity, Proprietary Technologies Platforms & Clinical Trials Insight 2030 - Product Image

Global Tumor Infiltrating Lymphocytes Therapy Market Opportunity, Proprietary Technologies Platforms & Clinical Trials Insight 2030

  • Report
  • 180 Pages
  • Global
From
Tumor Infiltrating Lymphocytes Market Outlook 2025-2034: Market Share, and Growth Analysis - Product Image

Tumor Infiltrating Lymphocytes Market Outlook 2025-2034: Market Share, and Growth Analysis

  • Report
  • 160 Pages
  • Global
From
Tumor Infiltrating Lymphocytes Market Report 2025 - Product Image

Tumor Infiltrating Lymphocytes Market Report 2025

  • Report
  • 250 Pages
  • Global
From
2025 Global Forecast for Tumor Infiltrating Lymphocytes Market (2026-2031): High Tech Outlook Report - Product Image

2025 Global Forecast for Tumor Infiltrating Lymphocytes Market (2026-2031): High Tech Outlook Report

  • Report
  • 132 Pages
  • Global
From
TIL Therapy - Pipeline Insight, 2025 - Product Image

TIL Therapy - Pipeline Insight, 2025

  • Drug Pipelines
  • 60 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.